|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Michael Gnant, MD, from the Medical University of Vienna in Vienna, Austria, and Sunil Verma, MD, MSEd, FRCPC, from the Toronto-Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada, along with a special eNewsflash and downloadable slides, discusses the topic of the anticancer effects of bisphosphonates in breast cancer focusing on the following data releases:
#10602: Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment
#512: Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial
#533: Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
#1002: Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results
|
| |
|
View the expert interview and opinion with Michael Gnant, MD, and Sunil Verma, MD, MSEd, FRCPC and access the downloadable slides
View eNewsflash
|
|
|
|
|
|
|
